combination-therapy

PERSIST (PERsister-State In-Silico Targeting): residual-state modelling of single-cell drug response for combination therapy prediction in EGFR-mutant NSCLC and TNBC

ML-driven platform for Glioblastoma drug recommendation using GDSC data. Features multi-model prediction (RF, XGBoost, NN, SVM, KNN), molecular similarity analysis (Tanimoto, MCS, GCN), pathway enrichment, drug interaction checking, and combination therapy optimization with interactive dashboard.

Synergy/Antagonism visualisation and calculation using Bliss Independence and Highest Single Agent (HSA)